Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-01

AUTHORS

François Chasset, Cécile Pages, Lucie Biard, Jennifer Roux, Irina Sidina, Isabelle Madelaine, Nicole Basset-Seguin, Manuelle Viguier, Nika Madjlessi-Ezra, Pierre Schneider, Martine Bagot, Matthieu Resche-Rigon, Céleste Lebbe

ABSTRACT

Ipilimumab is an anti-CTLA-4 antibody which has recently been approved in Europe as a monotherapy in the treatment of metastatic melanoma.We report a single-center study among patients treated within a Temporary Authorization for Use (TAU) protocol.We also performed a review of the literature involving expanded access program studies with a focus on factors associated with overall survival (OS).Patients and methodsThis retrospective, observational study included patients between June 2010 and July 2011 with a diagnosis of non-resectable stage III or IV melanoma with at least one previous line of chemotherapy. Treatment consisted of four courses of ipilimumab at a dose of 3mg/kg every three weeks.Results45 patients were included, among whom23 (51%) had brain metastases. 33 (71%) of the patients completed the induction phase. The best overall response rate (BORR) was 13% and median overall survival (OS) was 8 months (95%CI: 7 to 12). OS was not different between patients with brain metastases at baseline and those without (p = 0.10), regardless of BRAF V600E status (p = 0.61). OS was poorer in patients who were being treated with corticoids at baseline (p<0.001) or with LDH at baseline > 500 UI/ml (p = 0.008).ConclusionA subset of patients most likely to benefit from ipilimumab should be defined. In our series we found a negative association of baseline corticosteroids with OS. Unlike high LDH levels, BRAF V600 E status and brain metastases should not be barriers to the initiation of treatment. More... »

PAGES

36-44

References to SciGraph publications

  • 2014-02-16. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases in JOURNAL OF NEURO-ONCOLOGY
  • 2012-05-28. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2014-05-07. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-04-17. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-03-01. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-03-08. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-04-03. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-04-04. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 1999-09. Dexamethasone enhances CTLA-4 expression during T cell activation in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2013-10-25. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2013-01-09. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance in NATURE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1684/ejd.2014.2471

    DOI

    http://dx.doi.org/10.1684/ejd.2014.2471

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1079012774

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/25500362


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diagnostic Imaging", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Follow-Up Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "France", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glucocorticoids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intravenous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ipilimumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Metastasis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Skin Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chasset", 
            "givenName": "Fran\u00e7ois", 
            "id": "sg:person.0677622665.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677622665.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pages", 
            "givenName": "C\u00e9cile", 
            "id": "sg:person.01125647410.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125647410.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "APHP Department of Biostatistics and Medical Information, H\u00f4pital Saint-Louis, Saint-Louis, France", 
                "ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Biard", 
            "givenName": "Lucie", 
            "id": "sg:person.01365034601.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365034601.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Roux", 
            "givenName": "Jennifer", 
            "id": "sg:person.01264612026.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264612026.57"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sidina", 
            "givenName": "Irina", 
            "id": "sg:person.01312401464.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312401464.72"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.508487.6", 
              "name": [
                "APHP Department of Pharmacy H\u00f4pital, Saint-Louis, France", 
                "Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Madelaine", 
            "givenName": "Isabelle", 
            "id": "sg:person.0751337164.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751337164.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Basset-Seguin", 
            "givenName": "Nicole", 
            "id": "sg:person.01266110107.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266110107.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Viguier", 
            "givenName": "Manuelle", 
            "id": "sg:person.01302526630.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302526630.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Madjlessi-Ezra", 
            "givenName": "Nika", 
            "id": "sg:person.0703223764.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703223764.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schneider", 
            "givenName": "Pierre", 
            "id": "sg:person.01042751461.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042751461.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bagot", 
            "givenName": "Martine", 
            "id": "sg:person.0606303163.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606303163.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "APHP Department of Biostatistics and Medical Information, H\u00f4pital Saint-Louis, Saint-Louis, France", 
                "ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Resche-Rigon", 
            "givenName": "Matthieu", 
            "id": "sg:person.01036155166.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036155166.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462420.6", 
              "name": [
                "APHP Department of Dermatology, H\u00f4pital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France", 
                "INSERM U976, Universit\u00e9 Paris 7-Diderot, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lebbe", 
            "givenName": "C\u00e9leste", 
            "id": "sg:person.01054652653.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054652653.34"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s11060-014-1400-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048201517", 
              "https://doi.org/10.1007/s11060-014-1400-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature11814", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017875293", 
              "https://doi.org/10.1038/nature11814"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s000180050403", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035624915", 
              "https://doi.org/10.1007/s000180050403"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-012-1227-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039718387", 
              "https://doi.org/10.1007/s00262-012-1227-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1756-9966-32-82", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006895592", 
              "https://doi.org/10.1186/1756-9966-32-82"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-013-1418-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029173312", 
              "https://doi.org/10.1007/s00262-013-1418-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1756-9966-33-30", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023400666", 
              "https://doi.org/10.1186/1756-9966-33-30"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-12-116", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049608203", 
              "https://doi.org/10.1186/1479-5876-12-116"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-014-1545-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041405474", 
              "https://doi.org/10.1007/s00262-014-1545-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-10-107", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026934049", 
              "https://doi.org/10.1186/1479-5876-10-107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-014-1528-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039731191", 
              "https://doi.org/10.1007/s00262-014-1528-9"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2015-01", 
        "datePublishedReg": "2015-01-01", 
        "description": "AbstractIpilimumab is an anti-CTLA-4 antibody which has recently been approved in Europe as a monotherapy in the treatment of metastatic melanoma.We report a single-center study among patients treated within a Temporary Authorization for Use (TAU) protocol.We also performed a review of the literature involving expanded access program studies with a focus on factors associated with overall survival (OS).Patients and methodsThis retrospective, observational study included patients between June 2010 and July 2011 with a diagnosis of non-resectable stage III or IV melanoma with at least one previous line of chemotherapy. Treatment consisted of four courses of ipilimumab at a dose of 3mg/kg every three weeks.Results45 patients were included, among whom23 (51%) had brain metastases. 33 (71%) of the patients completed the induction phase. The best overall response rate (BORR) was 13% and median overall survival (OS) was 8 months (95%CI: 7 to 12). OS was not different between patients with brain metastases at baseline and those without (p = 0.10), regardless of BRAF V600E status (p = 0.61). OS was poorer in patients who were being treated with corticoids at baseline (p<0.001) or with LDH at baseline > 500 UI/ml (p = 0.008).ConclusionA subset of patients most likely to benefit from ipilimumab should be defined. In our series we found a negative association of baseline corticosteroids with OS. Unlike high LDH levels, BRAF V600 E status and brain metastases should not be barriers to the initiation of treatment.", 
        "genre": "article", 
        "id": "sg:pub.10.1684/ejd.2014.2471", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1102237", 
            "issn": [
              "1167-1122", 
              "1952-4013"
            ], 
            "name": "European Journal of Dermatology", 
            "publisher": "John Libbey Eurotext", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "25"
          }
        ], 
        "keywords": [
          "best overall response rate", 
          "single-center study", 
          "overall survival", 
          "brain metastases", 
          "metastatic melanoma", 
          "baseline corticosteroids", 
          "temporary authorization", 
          "courses of ipilimumab", 
          "dose of 3mg", 
          "median overall survival", 
          "high LDH levels", 
          "initiation of treatment", 
          "overall response rate", 
          "BRAF V600E status", 
          "use protocol", 
          "LDH levels", 
          "V600E status", 
          "observational study", 
          "E status", 
          "UI/", 
          "patients", 
          "stage III", 
          "response rate", 
          "ipilimumab", 
          "metastasis", 
          "melanoma", 
          "induction phase", 
          "previous lines", 
          "baseline", 
          "corticosteroids", 
          "treatment", 
          "Program Study", 
          "negative association", 
          "survival", 
          "status", 
          "monotherapy", 
          "MethodsThis", 
          "chemotherapy", 
          "corticoids", 
          "study", 
          "diagnosis", 
          "dose", 
          "weeks", 
          "antibodies", 
          "months", 
          "association", 
          "protocol", 
          "review", 
          "initiation", 
          "LDH", 
          "subset", 
          "course", 
          "negative impact", 
          "factors", 
          "levels", 
          "rate", 
          "authorization", 
          "barriers", 
          "literature", 
          "lines", 
          "impact", 
          "focus", 
          "series", 
          "Europe", 
          "phase"
        ], 
        "name": "Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids", 
        "pagination": "36-44", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1079012774"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1684/ejd.2014.2471"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "25500362"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1684/ejd.2014.2471", 
          "https://app.dimensions.ai/details/publication/pub.1079012774"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:59", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_653.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1684/ejd.2014.2471"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1684/ejd.2014.2471'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1684/ejd.2014.2471'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1684/ejd.2014.2471'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1684/ejd.2014.2471'


     

    This table displays all metadata directly associated to this object as RDF triples.

    339 TRIPLES      21 PREDICATES      121 URIs      102 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1684/ejd.2014.2471 schema:about N1f7ca74dcd31413a8af8ec50b86133a0
    2 N3dd0d197ef9d4e01a23d68f353282770
    3 N4f8e048f19ae477f87961f9caa9ca7d9
    4 N5e7111aed32f4f4180e10d4ef62b6e0d
    5 N6786aa1e17b441e792829bcca1ad0f7d
    6 N721e2c0089fb41e18a7063474898162a
    7 N72da69665f434fcfa176047022268026
    8 N75c5bad967a74693bd60252b94173ecc
    9 N7610cf93a1e8420f89a3cd1163ef0f29
    10 N9985774269a34d07b0aa4c36adfc7402
    11 N9d00c791dcdf41f1b61cf2369a590a8d
    12 Na74e0e8ca20347c98d5077853516b5eb
    13 Nb114cd0be80a4b67a63f9e0d60052a25
    14 Nb39c5d5de56f4af1938afda1c89a235f
    15 Nb6ff7eb4fad649368c3e8a378ca3d226
    16 Ne3266383980c44468a5b499ae3b23269
    17 Ne4a0d60d513342aaa8a2d88eb7c75960
    18 Ne6497d5454dd4438911e7a6ab5295296
    19 Nff119edd751347a6b7438eaa0414ee34
    20 anzsrc-for:11
    21 anzsrc-for:1112
    22 schema:author N0b601a8542b64a87991be39a965ff628
    23 schema:citation sg:pub.10.1007/s000180050403
    24 sg:pub.10.1007/s00262-012-1227-3
    25 sg:pub.10.1007/s00262-013-1418-6
    26 sg:pub.10.1007/s00262-014-1528-9
    27 sg:pub.10.1007/s00262-014-1545-8
    28 sg:pub.10.1007/s11060-014-1400-y
    29 sg:pub.10.1038/nature11814
    30 sg:pub.10.1186/1479-5876-10-107
    31 sg:pub.10.1186/1479-5876-12-116
    32 sg:pub.10.1186/1756-9966-32-82
    33 sg:pub.10.1186/1756-9966-33-30
    34 schema:datePublished 2015-01
    35 schema:datePublishedReg 2015-01-01
    36 schema:description AbstractIpilimumab is an anti-CTLA-4 antibody which has recently been approved in Europe as a monotherapy in the treatment of metastatic melanoma.We report a single-center study among patients treated within a Temporary Authorization for Use (TAU) protocol.We also performed a review of the literature involving expanded access program studies with a focus on factors associated with overall survival (OS).Patients and methodsThis retrospective, observational study included patients between June 2010 and July 2011 with a diagnosis of non-resectable stage III or IV melanoma with at least one previous line of chemotherapy. Treatment consisted of four courses of ipilimumab at a dose of 3mg/kg every three weeks.Results45 patients were included, among whom23 (51%) had brain metastases. 33 (71%) of the patients completed the induction phase. The best overall response rate (BORR) was 13% and median overall survival (OS) was 8 months (95%CI: 7 to 12). OS was not different between patients with brain metastases at baseline and those without (p = 0.10), regardless of BRAF V600E status (p = 0.61). OS was poorer in patients who were being treated with corticoids at baseline (p<0.001) or with LDH at baseline > 500 UI/ml (p = 0.008).ConclusionA subset of patients most likely to benefit from ipilimumab should be defined. In our series we found a negative association of baseline corticosteroids with OS. Unlike high LDH levels, BRAF V600 E status and brain metastases should not be barriers to the initiation of treatment.
    37 schema:genre article
    38 schema:isAccessibleForFree false
    39 schema:isPartOf N65de6d64628741fc9b6d163bc6a4f51e
    40 N7366029ef76f44f4813fcc03d5c8f797
    41 sg:journal.1102237
    42 schema:keywords BRAF V600E status
    43 E status
    44 Europe
    45 LDH
    46 LDH levels
    47 MethodsThis
    48 Program Study
    49 UI/
    50 V600E status
    51 antibodies
    52 association
    53 authorization
    54 barriers
    55 baseline
    56 baseline corticosteroids
    57 best overall response rate
    58 brain metastases
    59 chemotherapy
    60 corticoids
    61 corticosteroids
    62 course
    63 courses of ipilimumab
    64 diagnosis
    65 dose
    66 dose of 3mg
    67 factors
    68 focus
    69 high LDH levels
    70 impact
    71 induction phase
    72 initiation
    73 initiation of treatment
    74 ipilimumab
    75 levels
    76 lines
    77 literature
    78 median overall survival
    79 melanoma
    80 metastasis
    81 metastatic melanoma
    82 monotherapy
    83 months
    84 negative association
    85 negative impact
    86 observational study
    87 overall response rate
    88 overall survival
    89 patients
    90 phase
    91 previous lines
    92 protocol
    93 rate
    94 response rate
    95 review
    96 series
    97 single-center study
    98 stage III
    99 status
    100 study
    101 subset
    102 survival
    103 temporary authorization
    104 treatment
    105 use protocol
    106 weeks
    107 schema:name Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids
    108 schema:pagination 36-44
    109 schema:productId N556e2ad51ad846aba4671412e0c7d0e8
    110 Ndae85a49b5d44a8c983d09733b56c91b
    111 Ned8a6f561dd04502a11dab95c2606546
    112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079012774
    113 https://doi.org/10.1684/ejd.2014.2471
    114 schema:sdDatePublished 2022-09-02T15:59
    115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    116 schema:sdPublisher Nc42f8b2b17df4c8886e485a4c09dbcec
    117 schema:url https://doi.org/10.1684/ejd.2014.2471
    118 sgo:license sg:explorer/license/
    119 sgo:sdDataset articles
    120 rdf:type schema:ScholarlyArticle
    121 N0b601a8542b64a87991be39a965ff628 rdf:first sg:person.0677622665.28
    122 rdf:rest N63b10d95c4c14dd190e15ba58d23a322
    123 N129928b4c73f4076af17223047815c6e rdf:first sg:person.01054652653.34
    124 rdf:rest rdf:nil
    125 N1f7ca74dcd31413a8af8ec50b86133a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name France
    127 rdf:type schema:DefinedTerm
    128 N39ed569209cc4cf496cd962d71c42f1c rdf:first sg:person.01266110107.91
    129 rdf:rest Nf1cf0e7ac27447c7bf44f43a124c4f6f
    130 N3dd0d197ef9d4e01a23d68f353282770 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Humans
    132 rdf:type schema:DefinedTerm
    133 N3f4d8cccdf8847eca9251cbc14c8c646 rdf:first sg:person.01042751461.38
    134 rdf:rest Ne1e9c72e9c384137af6722cc520b1c41
    135 N497e821220bd4bee856838cb7a06fe52 rdf:first sg:person.01036155166.50
    136 rdf:rest N129928b4c73f4076af17223047815c6e
    137 N4f8e048f19ae477f87961f9caa9ca7d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Skin Neoplasms
    139 rdf:type schema:DefinedTerm
    140 N556e2ad51ad846aba4671412e0c7d0e8 schema:name doi
    141 schema:value 10.1684/ejd.2014.2471
    142 rdf:type schema:PropertyValue
    143 N5e7111aed32f4f4180e10d4ef62b6e0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Antibodies, Monoclonal
    145 rdf:type schema:DefinedTerm
    146 N63b10d95c4c14dd190e15ba58d23a322 rdf:first sg:person.01125647410.05
    147 rdf:rest N7b63fdb09d1e45aea631f9bef2d137eb
    148 N65de6d64628741fc9b6d163bc6a4f51e schema:volumeNumber 25
    149 rdf:type schema:PublicationVolume
    150 N6786aa1e17b441e792829bcca1ad0f7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Dose-Response Relationship, Drug
    152 rdf:type schema:DefinedTerm
    153 N721e2c0089fb41e18a7063474898162a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Aged
    155 rdf:type schema:DefinedTerm
    156 N72da69665f434fcfa176047022268026 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Aged, 80 and over
    158 rdf:type schema:DefinedTerm
    159 N7366029ef76f44f4813fcc03d5c8f797 schema:issueNumber 1
    160 rdf:type schema:PublicationIssue
    161 N75c5bad967a74693bd60252b94173ecc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Injections, Intravenous
    163 rdf:type schema:DefinedTerm
    164 N7610cf93a1e8420f89a3cd1163ef0f29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Middle Aged
    166 rdf:type schema:DefinedTerm
    167 N7b63fdb09d1e45aea631f9bef2d137eb rdf:first sg:person.01365034601.15
    168 rdf:rest Nb30d24ac25cc49daa4347ae82c6ae2d7
    169 N8c738022e7f44c829c5d1ade19299596 rdf:first sg:person.01312401464.72
    170 rdf:rest Ncfdc6de2b42045379059737add48ab04
    171 N9985774269a34d07b0aa4c36adfc7402 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Ipilimumab
    173 rdf:type schema:DefinedTerm
    174 N9d00c791dcdf41f1b61cf2369a590a8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Glucocorticoids
    176 rdf:type schema:DefinedTerm
    177 Na74e0e8ca20347c98d5077853516b5eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Diagnostic Imaging
    179 rdf:type schema:DefinedTerm
    180 Nb114cd0be80a4b67a63f9e0d60052a25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Adult
    182 rdf:type schema:DefinedTerm
    183 Nb30d24ac25cc49daa4347ae82c6ae2d7 rdf:first sg:person.01264612026.57
    184 rdf:rest N8c738022e7f44c829c5d1ade19299596
    185 Nb39c5d5de56f4af1938afda1c89a235f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Neoplasm Metastasis
    187 rdf:type schema:DefinedTerm
    188 Nb6ff7eb4fad649368c3e8a378ca3d226 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Male
    190 rdf:type schema:DefinedTerm
    191 Nc42f8b2b17df4c8886e485a4c09dbcec schema:name Springer Nature - SN SciGraph project
    192 rdf:type schema:Organization
    193 Ncfdc6de2b42045379059737add48ab04 rdf:first sg:person.0751337164.54
    194 rdf:rest N39ed569209cc4cf496cd962d71c42f1c
    195 Nd6fb53ab64e747ad971bb5ca2fc1f214 rdf:first sg:person.0703223764.65
    196 rdf:rest N3f4d8cccdf8847eca9251cbc14c8c646
    197 Ndae85a49b5d44a8c983d09733b56c91b schema:name pubmed_id
    198 schema:value 25500362
    199 rdf:type schema:PropertyValue
    200 Ne1e9c72e9c384137af6722cc520b1c41 rdf:first sg:person.0606303163.09
    201 rdf:rest N497e821220bd4bee856838cb7a06fe52
    202 Ne3266383980c44468a5b499ae3b23269 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Retrospective Studies
    204 rdf:type schema:DefinedTerm
    205 Ne4a0d60d513342aaa8a2d88eb7c75960 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Female
    207 rdf:type schema:DefinedTerm
    208 Ne6497d5454dd4438911e7a6ab5295296 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Follow-Up Studies
    210 rdf:type schema:DefinedTerm
    211 Ned8a6f561dd04502a11dab95c2606546 schema:name dimensions_id
    212 schema:value pub.1079012774
    213 rdf:type schema:PropertyValue
    214 Nf1cf0e7ac27447c7bf44f43a124c4f6f rdf:first sg:person.01302526630.97
    215 rdf:rest Nd6fb53ab64e747ad971bb5ca2fc1f214
    216 Nff119edd751347a6b7438eaa0414ee34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Melanoma
    218 rdf:type schema:DefinedTerm
    219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    220 schema:name Medical and Health Sciences
    221 rdf:type schema:DefinedTerm
    222 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    223 schema:name Oncology and Carcinogenesis
    224 rdf:type schema:DefinedTerm
    225 sg:journal.1102237 schema:issn 1167-1122
    226 1952-4013
    227 schema:name European Journal of Dermatology
    228 schema:publisher John Libbey Eurotext
    229 rdf:type schema:Periodical
    230 sg:person.01036155166.50 schema:affiliation grid-institutes:None
    231 schema:familyName Resche-Rigon
    232 schema:givenName Matthieu
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036155166.50
    234 rdf:type schema:Person
    235 sg:person.01042751461.38 schema:affiliation grid-institutes:grid.462420.6
    236 schema:familyName Schneider
    237 schema:givenName Pierre
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042751461.38
    239 rdf:type schema:Person
    240 sg:person.01054652653.34 schema:affiliation grid-institutes:grid.462420.6
    241 schema:familyName Lebbe
    242 schema:givenName Céleste
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054652653.34
    244 rdf:type schema:Person
    245 sg:person.01125647410.05 schema:affiliation grid-institutes:grid.462420.6
    246 schema:familyName Pages
    247 schema:givenName Cécile
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125647410.05
    249 rdf:type schema:Person
    250 sg:person.01264612026.57 schema:affiliation grid-institutes:grid.462420.6
    251 schema:familyName Roux
    252 schema:givenName Jennifer
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264612026.57
    254 rdf:type schema:Person
    255 sg:person.01266110107.91 schema:affiliation grid-institutes:grid.462420.6
    256 schema:familyName Basset-Seguin
    257 schema:givenName Nicole
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266110107.91
    259 rdf:type schema:Person
    260 sg:person.01302526630.97 schema:affiliation grid-institutes:grid.462420.6
    261 schema:familyName Viguier
    262 schema:givenName Manuelle
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302526630.97
    264 rdf:type schema:Person
    265 sg:person.01312401464.72 schema:affiliation grid-institutes:grid.462420.6
    266 schema:familyName Sidina
    267 schema:givenName Irina
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312401464.72
    269 rdf:type schema:Person
    270 sg:person.01365034601.15 schema:affiliation grid-institutes:None
    271 schema:familyName Biard
    272 schema:givenName Lucie
    273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365034601.15
    274 rdf:type schema:Person
    275 sg:person.0606303163.09 schema:affiliation grid-institutes:grid.462420.6
    276 schema:familyName Bagot
    277 schema:givenName Martine
    278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606303163.09
    279 rdf:type schema:Person
    280 sg:person.0677622665.28 schema:affiliation grid-institutes:grid.462420.6
    281 schema:familyName Chasset
    282 schema:givenName François
    283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677622665.28
    284 rdf:type schema:Person
    285 sg:person.0703223764.65 schema:affiliation grid-institutes:grid.462420.6
    286 schema:familyName Madjlessi-Ezra
    287 schema:givenName Nika
    288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703223764.65
    289 rdf:type schema:Person
    290 sg:person.0751337164.54 schema:affiliation grid-institutes:grid.508487.6
    291 schema:familyName Madelaine
    292 schema:givenName Isabelle
    293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751337164.54
    294 rdf:type schema:Person
    295 sg:pub.10.1007/s000180050403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035624915
    296 https://doi.org/10.1007/s000180050403
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1007/s00262-012-1227-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039718387
    299 https://doi.org/10.1007/s00262-012-1227-3
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1007/s00262-013-1418-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029173312
    302 https://doi.org/10.1007/s00262-013-1418-6
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1007/s00262-014-1528-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039731191
    305 https://doi.org/10.1007/s00262-014-1528-9
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.1007/s00262-014-1545-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041405474
    308 https://doi.org/10.1007/s00262-014-1545-8
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.1007/s11060-014-1400-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1048201517
    311 https://doi.org/10.1007/s11060-014-1400-y
    312 rdf:type schema:CreativeWork
    313 sg:pub.10.1038/nature11814 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017875293
    314 https://doi.org/10.1038/nature11814
    315 rdf:type schema:CreativeWork
    316 sg:pub.10.1186/1479-5876-10-107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026934049
    317 https://doi.org/10.1186/1479-5876-10-107
    318 rdf:type schema:CreativeWork
    319 sg:pub.10.1186/1479-5876-12-116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049608203
    320 https://doi.org/10.1186/1479-5876-12-116
    321 rdf:type schema:CreativeWork
    322 sg:pub.10.1186/1756-9966-32-82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006895592
    323 https://doi.org/10.1186/1756-9966-32-82
    324 rdf:type schema:CreativeWork
    325 sg:pub.10.1186/1756-9966-33-30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023400666
    326 https://doi.org/10.1186/1756-9966-33-30
    327 rdf:type schema:CreativeWork
    328 grid-institutes:None schema:alternateName ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France
    329 schema:name APHP Department of Biostatistics and Medical Information, Hôpital Saint-Louis, Saint-Louis, France
    330 ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France
    331 rdf:type schema:Organization
    332 grid-institutes:grid.462420.6 schema:alternateName INSERM U976, Université Paris 7-Diderot, Paris, France
    333 schema:name APHP Department of Dermatology, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010, Paris, France
    334 INSERM U976, Université Paris 7-Diderot, Paris, France
    335 rdf:type schema:Organization
    336 grid-institutes:grid.508487.6 schema:alternateName Université Paris 7-Diderot, Paris, France
    337 schema:name APHP Department of Pharmacy Hôpital, Saint-Louis, France
    338 Université Paris 7-Diderot, Paris, France
    339 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...